| Literature DB >> 33738706 |
Konstantin A Demin1, Aleksandr G Refeld1, Anna A Bogdanova1, Evgenya V Prazdnova1, Igor V Popov2, Olga Yu Kutsevalova3, Alexey M Ermakov2, Anzhelica B Bren1,2, Dmitry V Rudoy2, Vladimir A Chistyakov1, Richard Weeks4, Michael L Chikindas5,6,7.
Abstract
Pathogenic Candida and infections caused by those species are now considered as a serious threat to public health. The treatment of candidiasis is significantly complicated by the increasing resistance of pathogenic strains to current treatments and the stagnant development of new antimycotic drugs. Many species, such as Candida auris, have a wide range of resistance mechanisms. Among the currently used synthetic and semi-synthetic antifungal drugs, the most effective are azoles, echinocandins, polyenes, nucleotide analogs, and their combinations. However, the use of probiotic microorganisms and/or the compounds they produce is quite promising, although underestimated by modern pharmacology, to control the spread of pathogenic Candida species.Entities:
Keywords: Antifungal drugs; Biofilm formation; Candida; Probiotics; Resistance
Mesh:
Substances:
Year: 2021 PMID: 33738706 DOI: 10.1007/s12602-021-09776-6
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN: 1867-1306 Impact factor: 4.609